Physician profile
Joan L Walker
NPI 1477521839
$10,514.10
in general payments reported to CMS, 2019-2025
14 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.30 · 2023: $8,071 · 2024: $2,297 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,845 · Travel and Lodging: $1,092 · Food and Beverage: $565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,845.00 |
| Travel and Lodging | $1,092.28 |
| Food and Beverage | $564.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10,228.52 | 2023-2025 | Keytruda, Lynparza |
| Eisai INC. | $51.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.49 | 2023-2024 | Enhertu, Lynparza |
| Bard Peripheral Vascular, INC. | $25.05 | 2025 | Trek |
| Astellas Pharma US INC | $22.21 | 2024 | Veozah |
| Tersera Therapeutics LLC | $20.90 | 2023 | Zoladex |
| Genmab U.S., INC. | $20.56 | 2025 | Tivdak |
| Daiichi Sankyo INC. | $19.28 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $19.19 | 2025 | Jemperli, Zejula |
| Seagen INC. | $17.33 | 2023 | Tukysa |
| Myriad Genetic Laboratories, INC. | $15.60 | 2024 | Myrisk |
| Novartis Pharmaceuticals Corporation | $14.45 | 2024 | |
| Stemline Therapeutics INC. | $13.28 | 2023 | Orserdu |
| Clovis Oncology, INC. | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.